MST1R Antibody, Biotin conjugated

Code CSB-PA015056LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) MST1R Polyclonal antibody
Uniprot No.
Target Names
MST1R
Alternative Names
c met related tyrosine kinase antibody; CD136 antibody; CD136 antigen antibody; CDw136 antibody; Macrophage stimulating 1 receptor (c met related tyrosine kinase) antibody; Macrophage stimulating 1 receptor antibody; Macrophage stimulating protein receptor alpha chain antibody; MACROPHAGE STIMULATING PROTEIN RECEPTOR antibody; Macrophage stimulating protein receptor beta chain antibody; Macrophage-Stimulating 1 Receptor (MST1R) antibody; Macrophage-stimulating protein receptor beta chain antibody; MSP receptor antibody; Mst1r antibody; MST1R variant RON30 antibody; MST1R variant RON62 antibody; NPCA3 antibody; p185 RON antibody; p185-Ron antibody; Protein-tyrosine kinase 8 antibody; PTK 8 antibody; ptk8 antibody; PTK8 protein tyrosine kinase 8 antibody; Recepteur d鈥檕rigine nantais (RON) antibody; RON antibody; RON protein tyrosine kinase antibody; RON variant E2E3 antibody; RON_HUMAN antibody; Soluble RON variant 1 antibody; Soluble RON variant 2 antibody; Soluble RON variant 3 antibody; Soluble RON variant 4 antibody; Stem cell derived tyrosine kinase antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Macrophage-stimulating protein receptor protein (1175-1400AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.
Gene References into Functions
  1. the cis-regulatory landscape that determines alternative splicing of exon 11 in the proto-oncogene MST1R (RON), was examined. PMID: 30120239
  2. this study demonstrates the functional significance of RON during prostate cancer progression and provides a strong rationale for targeting RON signaling in prostate cancer as a means to limit resistance to androgen deprivation therapy. PMID: 30121008
  3. Study conclude that the splice variants of RON lacking exon 11 and exons 11-13 were detected in several lung cancer cell lines. Novel variant formed by skipping exons 11-13, the sequence of which code for transmembrane region, is predicted to code for a truncated isoform that may be secreted out. PMID: 30223007
  4. RONDelta165E2 variant promoted tumor progression while activating the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma. PMID: 28388571
  5. These findings indicate that RON and c-Met facilitate metastasis through ERK1/2 signaling and that targeting RON and c-Met with foretinib may be an attractive therapeutic option for suppressing Prostate cancer metastasis PMID: 28440432
  6. Forkhead box C1 protein (FOXC1) promotes melanoma cell function by regulating macrophage stimulating 1 receptor (MST1R) and activating MST1R/PI3K/AKT pathway. PMID: 27533251
  7. RON has a role in cancer-induced bone destruction and osteoporosis PMID: 28123075
  8. RON isoforms may comprise half of total RON transcript in human pancreatic cancer and their expression is regulated at least in part by promoter hypermethylation. PMID: 27323855
  9. High RON expression is associated with castration resistant prostate cancer. PMID: 26872377
  10. hnRNP A1 directly binds to the 5' untranslated region of the RON mRNA and activates its translation through G-quadruplex RNA secondary structures PMID: 26930004
  11. Findings indicate a role of the RON tyrosine kinase receptor in pancreatic cancer and suggest RON as a potential therapeutic target. PMID: 26477314
  12. High expression of RON is associated with drug resistance in bladder cancer. PMID: 28075465
  13. complete loss of one or both MET and RON, as well as their overexpression, is a poor prognostic factor in patients with extrahepatic cholangiocarcinoma, probably due to the high rate of lymph-node metastasis PMID: 27919987
  14. Study identified four novel uniquely spliced RON transcripts in small cell lung carcinoma (SCLC) and Non-SCLC cell lines. PMID: 26775595
  15. the MST1R variant c.G917A:p.R306H is highly associated with nasopharyngeal carcinoma (odds ratio of 9.0). PMID: 26951679
  16. Results show that under hypoxia, nuclear RON activates non-homologous end joining DNA repair by interacting with Ku70 and DNA-PKcs and confers chemoresistance. PMID: 26772202
  17. Aberrant glycosylation of the RON receptor was shown as an alternative mechanism of oncogenic activation. PMID: 26721331
  18. Data demonstrated upregulated RON isoform expression and significant changes in splicing factor expression in primary ovarian cancer suggesting a regulatory interplay of splicing factor and RON alternative splicing pattern in ovarian cancer. PMID: 25997828
  19. Activation of RON as an alternate mechanism in the development of CRPC. PMID: 26152593
  20. the prognostic significance of MET is limited in early stage disease. MET+/RON+ patients had higher overall recurrence rates than those with the other expression patterns PMID: 25874493
  21. RON expression in endometrial adenocarcinoma was significantly higher than that in normal endometrial tissues. PMID: 26189249
  22. Studies demonstrate that DEK overexpression, due in part to Ron receptor activation, drives breast cancer progression through the induction of Wnt/beta-catenin signaling. PMID: 24954505
  23. approach identified 18 kinase and kinase-related genes whose overexpression can substitute for EGFR in EGFR-dependent PC9 cells, and these genes include seven of nine Src family kinase genes, FGFR1, FGFR2, ITK, NTRK1, NTRK2, MOS, MST1R, and RAF1. PMID: 25512530
  24. SRSF2 promotes exon 11 inclusion of Ron proto-oncogene through targeting exon 11. PMID: 25220236
  25. Results pointed to a novel function for RON as a transcriptional regulator that promotes the survival of cancer cells subjected to hypoxia. PMID: 24903148
  26. Data shows that MET and RON are regulated by PAX8 in non-small cell lung cancer. PMID: 24628993
  27. Stusies indicate that RON receptor tyrosine kinase is overexpressed and activated in pancreatic tumor specimens. PMID: 24518495
  28. RON expression was dominantly observed in laryngeal SCC tissues relative to adjacent normal mucosa. Knockdown of RON resulted in significantly reduced cell invasion and cell migration in human laryngeal SCC cells. PMID: 24287326
  29. RON promotes breast cancer metastasis through altered DNA methylation. PMID: 24388747
  30. Through double-base and single-base substitution analysis of the 2-nt RNA, this study demonstrated that the GA, CC, UG and AC dinucleotides on exon 11, in addition to the wild-type AG sequence, function as enhancers for exon 11 inclusion of the Ron pre-mRNA. PMID: 24189591
  31. intron retention in the RON gene was investigated. PMID: 24155930
  32. findings identify the pathway of Ron-c-Abl-PCNA as a mechanism of oncogene-induced cell proliferation, with potentially important implications for development of combination therapy of breast cancer PMID: 23542172
  33. Suggest that MET and MST1R are independent prognostic factors in classical classical Hodgkin's lymphoma, and may allow the identification of a subgroup of cHL patients who require more intensive therapy. PMID: 23558571
  34. Data suggest that oncogenic RON160 is frequently expressed in primary invasive ductal, lobular, and lymph node-involved breast cancer tissues; RON160 overexpression is predominantly observed in invasive ductal and lymph node-involved cases. PMID: 23597200
  35. The MET(-) RON(-) phenotype retained its prognostic impact after subgroup analysis. PMID: 23745832
  36. Demonstrate of the important role of RON in mediating lapatinib resistance in breast cancer cells. PMID: 23811285
  37. the function of RON in tumors may be multidimensional, not just as a tumor suppressor or oncogene. PMID: 23483216
  38. RON may influence carcinogenesis in a number of systemic malignancies. PMID: 23294341
  39. Ron synergises with EGFR to confer certain adverse features in head and neck squamous cell carcinomas. PMID: 23799848
  40. RON expression is not associated with prognosis or therapeutic responsiveness in resected pancreatic cancer. PMID: 22958871
  41. results suggest cytoplasmic phosphorylated RON is a potential marker for poor prognosis in Esophageal squamous cell carcinomapatients. PMID: 22086736
  42. study presents two novel splicing variants of RON in the partial splicing events that involve exons 5 and 6; the difference of these two isoforms is the inclusion or skipping of intron 6 PMID: 22993024
  43. High RON expression is associated with acute myeloid leukemia. PMID: 22902361
  44. These results suggest an important role of RON in the tumorigenesis and metastasis of nasopharyngeal carcinoma. PMID: 22974584
  45. Knockdown of RON inhibited invasive growth & the activation of oncogenic signaling pathways including Akt, MAPK and beta-catenin. RON up-regulation was associated with tumor size, lymphatic metastasis, invasiveness, tumor stage and poor survival. PMID: 23235762
  46. A new splice variant of RON suggests a novel role for the RON receptor in the progression of metastasis in colorectal cancer. PMID: 22975341
  47. the structure of RON Sema-PSI domains at 1.85 A resolution PMID: 22848655
  48. High RON expression is associated with small and non-small cell lung cancers. PMID: 22585712
  49. tumor promoter induces RON expression via Egr-1, which, in turn, stimulates cell invasiveness in AGS cells PMID: 22095683
  50. Elevated RON expression may contribute to the occurrence, progression and metastasis of non-small cell lung cancer(NSCLC), inferring that it could be useful as a new prognostic indicator for patients with NSCLC. PMID: 22613539

Show More

Hide All

Involvement in disease
Nasopharyngeal carcinoma, 3 (NPCA3)
Subcellular Location
Membrane; Single-pass type I membrane protein.
Protein Families
Protein kinase superfamily, Tyr protein kinase family
Tissue Specificity
Expressed in colon, skin, lung and bone marrow.
Database Links

HGNC: 7381

OMIM: 255995

KEGG: hsa:4486

STRING: 9606.ENSP00000296474

UniGene: Hs.517973

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*